Totally drug resistant tuberculosis - A fact or myth?

Indian Journal of Tuberculosis

Volumn 59, Issue 4, 2012, Pages 190-193

  Behera, D ^a,b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b LRS Institute of Tuberculosis and Respiratory Diseases   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

BACTERIUM CULTURE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; EDITORIAL; HUMAN; LABORATORY TEST; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; QUALITY CONTROL; SCIENTIFIC LITERATURE; TERTIARY HEALTH CARE;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INCIDENCE; INDIA; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84872127410     PISSN: 00195707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Correspondence: Totally Drug-Resistant Tuberculosis in India. Clin Infect Dis 2012; 54: 579-81.
2. Loewenberg S. India reports cases of totally drug-resistant tuberculosis. Lancet 2012; 379: 205.
3. Udwadia ZF. Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology 2012; 17: 741-2.
4. Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 2012; 67: 286-8
5. Myneedu VP, Visalakshi P, Verma AK, Behera D, Bhalla M. Prevalence of XDR-TB cases - A retrospective study from a tertiary care TB Hospital. Indian J Tuberc 2011; 58: 54-9.
6. Paramsivan CN, Rehman F, Wares F, Sunder Mohan N, Sundar S, Devi S, et al. First and Second-line drug resistance pattern among previously treated tuberculosis patients in India (short communication). Int J Tuberc Lung Dis 2010; 14: 243-6.
7. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009; 13: 1154-60.
8. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drugresistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-5.
9. Kim S J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-9.
10. Kam KM, Sloutsky A, Yip CW, Bulled N, Seung KJ, Zignol M, et al. Determination of critical concentrations of secondline anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14: 282-8.
11. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-40.
12. Van Deun A, Wright A, Zignol M, et al. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011; 15: 116-24.
13. Fattorini L, Migliori GB, Cassone A, Mustazzolu A, Piccaro G, Filippini P, Cirillo DM, Borroni E. Italian Multicentre Study on Resistance to Anti-tuberculosis Drugs Group. Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy. Eur Respir J 2012; 39: 1263-6.
14. World Health Organization. Policy guidance on drug susceptibility testing (DST) of second-line anti-tuberculosis drugs. WHO/HTM/TB/2008.
15. Singla R, Caminero JA, Jaiswal A, Singla N, Gupta S, Bali RK, Behera D. Linezolid, an effective and cheap drug in MDRTB treatment failure patients in India. Eur Respir J 2012; 39: 956-62.
16. Abbate E, Vescovo M, Natiello M, Cufré M, García A, Gonzalez Montaner P, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother 2012; 67: 473-7.